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Abstract
Background: Benign Intracranial Hypertension (BIH) may be caused, at least in part, by
intracranial sinus thrombosis. Thrombosis is normally due to derangements in blood coagulation
cascade which may predispose to abnormal clotting activation or deficiency in natural inhibitors'
control. The aim of the study is to examine the strength of the association between risk factors for
thrombosis and BIH.
Patients and methods: The incidence of prothrombotic abnormalities among a randomly
investigated cohort of 17 patients with BIH, was compared with 51 healthy subjects matched for
sex, age, body mass index, height and social background.
Results: The number of subjects with protein C deficiency was significantly higher in patients than
in controls (3 vs 1, p < .001; Fisher Exact Test). Moderate to high titers of anticardiolipin antibodies
(β2-Glycoprotein type I) were found in 8 out of 17 patients.
Increased plasma levels of prothrombin fragment 1+2, fibrinopeptide A (FPA), and PAI-1 were
demonstrated in patients group (5.7 ± 1.15 nM vs 0.45 ± 0.35 nM; 8.7 ± 2.5 ng/mL vs 2.2 ± 1.25 ng/
mL; 45.7 ± 12.5 ng/mL vs 8.5 ± 6.7 ng/mL, respectively; p < .001; Fisher Exact Test). Gene
polymorphisms for factor V Leiden mutation, prothrombin mutation 20210 A/G, MTHFR 677 C/
T, PAI-1 4G/5G, ACE I/D were detected in 13 patients.
Discussion: In agreement with other authors our data suggest a state of hypercoagulability in BIH
associated with gene polymorphisms. Our findings also showed that mutations in cardiovascular
genes significantly discriminate subjects with a BIH history. The association between coagulation
and gene derangements, usually regarded to as cryptogenic, may suggest a possible pathogenetic
mechanism in BIH. So, a prothrombotic tendency may exist that would, at least in part, explain
some cases of BIH.
Although based on a small population, these findings raise the exciting possibility of using these 
haemostatic factors as markers for selecting high-risk subjects in BIH disease.
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Benign Intracranial Hypertension (BIH) is due to an
increased intracranial pressure of unknown origin [1].
One of the possible causes of BIH may be due to intracra-
nial venous sinus thrombosis [2], although cerebral angi-
ograms could be normal in patients affected by BIH
associated with conditions highly predisposing to venous
thrombosis. This raises the possibility that unrecognised
non-occlusive venous thrombus might impede cerebral
spinal fluid (CSF) drainage [3].
Thrombosis is normally due to derangements in coagula-
tion system which may predispose to abnormal clotting
activation or to a deficient control of natural clotting
inhibitors [4,5]. The risk of thrombosis is increased by fac-
tors that cause hypercoagulability or venous stasis, such as
oral contraceptives, pregnancy or post-partum period,
trauma, prolonged immobilization. However, the risk of
thrombosis is also increased by hypercoagulable states
due to inherited abnormalities of the coagulation system,
such as factor V (FV) R506Q mutation, which causes
resistance to activated protein C (PC) [6], prothrombin
A20210G gene polymoprphism [7], and deficiencies of
antithrombin III (AT III), PC or protein S (PS) [8].
Acquired abnormalities such as the presence of antiphos-
pholipid antibodies can also induce an increased risk of
thrombosis [9].
Increased plasma levels of the main inhibitor of fibrinol-
ysis, plasminogen activator inhibitor type 1 (PAI-1), have
been documented in subjects who subsequently devel-
oped myocardial infarction [10], while its association
with venous thromboembolism is still matter of discus-
sion.
The renin-angiotensin pathway plays a role in the regula-
tion of PAI-1 plasma levels [11]. An insertion (I)/deletion
(D) polymorphism of the angiotensin-convertying
enzyme (ACE) gene has been related to plasma and cellu-
lar ACE levels [12]. Compared to the DD frequency in a
control population, the frequency of the ACE DD geno-
type is higher in individuals with ischemic cardiovascular
disease suggesting that ACE gene variant may contribute
to the pathogenesis of this disease.
The C→T 677 transition in the methylen-thetrahydropho-
late reductase (MTHFR) gene [13] have widened the spec-
trum of inherited thrombophilia through
hyperhomocysteinemia.
So an activation of blood coagulation may predispose to
thrombin formation and fibrin deposition that may lead
to thrombosis of large or small vessels.
In this study, we examined the strength of the association
between risk factors for thrombosis and BIH disease.
Patients and methods
Patients
Seventeen unrelated patients with a documented diagno-
sis of idiopathic benign intracranial hypertension (BIH)
according to World Health Organization criteria were
studied retrospectively (4 men and 13 women; median
age 31 years; range 15 to 55). They were referred to our
thrombosis laboratory between February 1998 and May
1999 for a complete screening.
None of them had overt evidence of autoimmune or neo-
plastic disease. Subjects under anticoagulant or contracep-
tive treatment were previously excluded from the study.
The clinical records and the objective documentations of
BIH were reviewed by two neurologists to confirm the
diagnosis, based on clinical symptoms and signs of
increased intracranial pressure (i.e. increased cerebrospi-
nal fluid pressure, Computed Tomography and Nuclear
Magnetic Resonance imagines with normal to small sym-
metrical ventricles).
Healthy controls
Fifty-one healthy persons (30 men and 21 women;
median age 32; range 19 to 52)_matched for sex, age, geo-
graphic origin, and level of education were enrolled as
healthy controls in the study. They came from a popula-
tion of biologically unrelated friends of the patients.
A thorough anamnesis was recorded for both patients and
controls in order to know common risk factors for cardio-
vascular diseases (i.e. smoking, hypertension, diabetes,
dyslipidemia, oral contraceptives use, personal and\or
familial history of venous thromboembolism or cardio-
cerebrovascular disease.
All subjects (i.e. patients and healthy controls) gave their
written informed consent to the study.
Laboratory tests
Blood samplings were performed for both cases and con-
trols before 10.00 a.m. with subjects fasting and having
rested for at least 20 minutes. Blood was collected in vac-
uum tubes contaning 3.8 percent (wt/vol) sodium citrate
as anticoagulant. Plasma was then obtained by centrifuga-
tion at 2000 × g for 20 minutes, swap-frozen in liquid
nitrogen and stored at -80°C within 2 h from collection.
Blood samples in cases were collected between 6 and 24
months after the acute episode.
All cases were receiving secondary prophylaxis with either
aspirin or ticlopidine, and none of them was on anticoag-Page 2 of 6
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weight heparin. Laboratory measurements were subse-
quently performed in both cases and controls within 1
month from blood collection.
Prothrombin Time (PT) and Activated Partial Thrombo-
plastin Time (APTT) were carried out according to Mani-
facturers recommendations. Fibrinogen (Fg) plasma
levels were assayed by the Clauss functional method. All
the measurements were determined on an automated
coagulometer (ACL 2000, Instrumentation Laboratory,
Milan).
Antithrombin III (ATIII) and Plasminogen (PLG) were
determined by chromogenic methods (Chromogenix,
Molndal; Sweden).
Antithrombin was further characterized by measuring
antigen levels by immunoelectrophoresis with a poli-
clonal antibody (Stago, Asmieres; France). Protein C (PC)
activity was assayed by a clotting assay (Pro Clot, Instru-
mentation Laboratory, Milan; Italy). Protein C antigen
levels were also measured by enzyme-linked immuno-
sorbent assay (ELISA) with polyclonal antibodies (Dako,
Glostrup; Denmark). Total protein S (total-PS) antigen
was measured by ELISA with polyclonal antibodies
(Dako). Free protein S (free-PS) was measured in the same
way after precipitation of the C4 binding protein-protein
S complex with polyethylene glycol 6000 (final concen-
tration 3.5 percent) or directly by ELISA with a commer-
cial kit that uses a specific monoclonal antibody
(Asserachrom Free Protein S, Stago; France).
The diagnosis of poor response to anticoagulant action of
activated protein C employed an APTT assay according to
Dahlback and colleagues, with and without activated PC
and in presence of an immunodepleted FV plasma
(Instrumentation Laboratory; Milan) [14].
(Bouty, Milan; Italy) and Plasminogen Activator Inhibitor
Type I (PAI-I) antigen levels were measured by ELISA
(Bouty, Milan; Italy).
The measurements of prothrombin fragment 1+2 (F1+2),
fibrinopeptide A (FPA) were assayed using an enzyme-
linked immunosorbent test (ELISA method) (Enzygnost,
Bhering, Scoppito, Italy), while Dimers-D (D-Dimer [s])
were tested with a specific kit (DILA HemosIL Dimertest
Latex, Instrumental Laboratory, Milan, Italy).
DNA was extracted from peripheral blood using standard
international procedures.
DNA analysis to identify a transition from guanine to ade-
nine at position 1691 in the coagulation factor V gene was
carried out as described by de Ronde and Bertina [15].
Screening for the MTMFR C->T 677 substitution was per-
formed by amplification of a 198 bp DNA fragment fol-
lowed by Hinf I digestion as described with modifications
[13].
The PAI-1 4G/5G polymorphism was evaluated as previ-
ously reported [16].
The PCR technique, primers, and experimental conditions
employed for the ACE genotyping were the ones suggested
by Rigat et al. with some modifications [17].
Statistical analysis
All the computations were perfomed according to the Sta-
tistical Package for Social Science (SPSS 6.1 for Macin-
tosh) [18].
The frequencies of the alleles and genotypes among cases
and controls were counted and compared by the chi-
square test with the values predicted by assumption of the
Hardy-Weinberg equilibrium. Chi-square analysis or
Fisher exact-test were used to compare differences
between discrete parameters. The differences between
cases and controls were analysed by impaired Student's
test for coagulation parameters, and by the Kruskall-Wal-
lis test for age, according to their observed distribution.
Multiple logistic analysis was performed by using LOGIS-
TIC procedure for SPSS.
All the results are given as mean ± standard deviation
(SD). A value of p < 0.05 was considered significant.
Results
Clinical characteristics of studied subjects as a whole are
shown in Table 1. Cases had the same age of healthy sub-
jects; there was the same number of smokers among
patients and controls and less often alcohol consumers
(O.R. 0.55; 95% C.I., 0.21 to 0.65). Among subjects with
pseudotumor cerebri there was a higher proportion of dia-
betics (O.R. 5.75; 95% C.I., 3.01 to 7.45), hypertensives
(O.R. 8.11; 95% C.I., 3.40 to 18.15).
The two groups also differed for the number of hyperlipe-
demics (O.R. 6.25; 95% C.I., 4.05 to 8.72) and users of
oral contraceptives (O.R. 5.15; 95% C.I., 3.65 to 7.21).
In addition, more frequently than controls, cases had an
episode of venous thromboembolism (O.R. 7.60; 95%
C.I., 3.50 to 16.05) and a family history of ischemic stroke
(O.R. 9.15; 95% C.I., 6.75 to 17.05).Page 3 of 6
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two different groups of subjects, such as levels of plas-
minogen and t-PA.
No control or patient carried inherited abnormalities of
antithrombin III or PS. The number of subjects with PC
deficiency was significantly higher in patients than in con-
trols (3 vs. 1 p < 0.001, Fisher Exact test).
Among controls only one subject showed a poor response
to APC with FV gene R506Q mutation at heterozygous
state (Table 2). Among cases, 2 individuals showed a poor
response to anticoagulant action of APC (<0.75, which
represents the cut-off point in our general population).
One patient carried FV mutation R506Q at heterozygous
state; the other subject did not show any mutation in FV
gene, thus showing an acquired APC-resistance.
Moderate to high titers of IgG and IgM anticardiolipin
antibodies (β2 GPI) were formed in 8 out of 17 patients
(above the cut-off point of 10.5 U GPL/L and 9.5 U MPL/
L, respectively). Among cases the mean values ± SD of Ig
G β2 GPI and IG M β2 GPI were 22.5 ± 11.5 U GPL/mL
and 14.5 ± 6.8 U MPL/mL respectively. Among controls
the mean values ± SD of Ig G β2 GPI and Ig M β2 GPI were
0.58 ± 0.30 U GPL/mL and 0.38 ± 0.25 U MPL/mL, respec-
tively (p < .001 and p < .001, Fisher Exact test).
Increased plasma levels of prothrombin fragment 1+2,
FPA, D-Dimer(s) and PAI were demonstrated in patients
group (5.7 ± 1.15 nM vs. 0.45 ± 0.35 nM, 8.7 ± 2.5 ng/mL
vs. 2.2 ± 1.25 ng/mL; 375 ± 65 ng/mL vs. 225 ± 75 ng/mL;
45.7 ± 12.5 ng/mL vs 8.5 ± 6.7 ng/mL, respectively; Fisher
Exact test).
As shown in Table 3, carriers of the FV R506Q mutation
were 1 (6%) at heterozygous state among cases, and 1
(2%) at heterozygous state among controls. The O.R.
associated with FV R506Q was 3.7 (95% C.I., 1.78 to 5.75
X2 = 6.2, p = .01).
DNA analysis for the prothrombin A 20210 mutation
demonstrated 1 heterozygous carrier (6 %, 95% C.I., 2.05
to 9.55; X2 = 6.2, p = .012) among patients and 1 hetero-
zygous carrier among healthy subjects (2 %, 95% C.I.,
1.05 to 3.65). Among patients, 3 individuals (18 %, 95%
C.I., 12.05 to 24.55; X2 = 9.6, p = .002) were homozygous
for the T allele of the MTHFR gene and 7 individuals (41
%, 95% C.I., 24.05 to 59.55; X2 = 13.4, p = <.0001) were
heterozygotes for the same defect vs 6 subjects (12 %,
95% C.I., 7.35 to 17.65) with homozygosity for the T
Table 2: Haemostatic parameters in pztients with BIH and controls. Values are expressed as main ± SD
Patients Healthy Controls P value
PT(sec) 12 ± 0,5 11,5 ± 0,8 0.18, ns
aPTT (sec) 30 ± 2,5 31,5 ± 3,4 0.09, ns
Fibrinogen (mg/dl) 340 ± 80,7 360 ± 68,2 0.32, ns
ATIII (%) 72 ± 16,5 76 ± 14,7 0.34, ns
PG (%) 80 ± 14,7 74,5 ± 15,2 0.19, ns
t-PA(ng/ml) 6,8 ± 3,7 7,5 ± 4,8 0.58, ns
PAI-l(ng/ml) 45.7 ± 12.5 8.5 ± 6.7 < 0.0001, s
FPA (ng/ml) 8.7 ± 2.5 2.2 ± 1.25 < 0.0001, s
F1+2 (nM/l) 5.7 ± 1.15 0.45 ± 0.35 0.0001, s
D-dimers (ng/ml) 375 ± 65 225 ± 75 < 0.0001, s
PC(%) 64 ± 7.5 87 ± 14.5 < 0.0001, s
PS (%) 97 ± 23 103 ± 12 0.16, ns
Aβ2IgM (UM/l) 14.5 ± 6.8 0.38 ± 0.25 < 0.0001, s
Aβ2IgG(UG/l) 22.5 ± 11.5 0.58 ± 0.30 < 0.0001, s
Prothrombin Time: PT; Activated Partial Prothrombin Time: aPTT;
Antithrombin: AT III, Plasminogen: PG; tissue-Plasminogen Activator; t-PA, Plasminogen Activator Inhibitor type-1: PAI-1; Fibrinopeptide-A: FPA; 
Prothrombin Fragment 1+2: F1+2; Protein C activity: PC; Protein S activity: PS; IgM anticardiolipin antibodies Ig M and Ig G: Aβ2IgM and Aβ2IgG; s: 
significant; ns: not significant.
Table 1: Clinical Characteristics of patients and healthy subjects
Patients (17) Healthy Controls (51)
Men 4 30
Women 13 21
Age (IQR) 31 (15–55) 32 (19–51)Page 4 of 6
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zigosity of control group (31 %, 95% C.I., 19.05 to
46.07).
Genotype analysis of the PAI-1 gene showed that 6 sub-
jects were heterozygous for 4G/5G polymorphism among
patients (35%, 95% C.I., 21.05 to 39.60; X2 = 3.5, p = .06)
and 3 subjects among patients showed homozygosity for
4G allele (18 %, 95% C.I., 12.25 to 23.15; X2 = 5.03, p =
.02), while 26 individuals were heterozygous for 4G/5G
gene polymorphism (51 %, 95% C.I., 38.75 to 69.04) and
10 were homozygotes for 4G allele (19 %, 95% C.I., 11.85
to 24.14) among controls.
ACE gene I/D polymorphism was evidenciated in 8
patients at heterozygous state (I/D, 47 %, 95% C.I., 31.05
to 57.20; X2 = 10.08, p = .001) and in 4 patients at
homozygous state (D/D 23 %, 95% C.I., 14.15 to 33.45;
X2 = 15.55, p = <.0001) while 22 healthy subjects were
heterozygotes for the same mutation (43 %, 95% C.I.,
28.85 to 61.25) and 7 healthy subjects were homozygotes
(11 %, 95% C.I., 2.05 to 9.55).
Discussion
Abnormalities of the clotting system such as natural anti-
coagulant deficiencies, resistance to anticoagulant action
of APC, derangements in fibrinolytic pathway or an
hypercoagulable state have been recognized as clear risk
factors for venous thromboembolism [8]. Their role, how-
ever, in BIH is still matter of discussion [19].
Recent findings have suggested that intracranial venous
sinus thrombosis, favoured by thrombophilia/hypofibri-
nolysis, may cause BIH, determining an obstruction to
cerebro-spinal fluid resorption-outflow [20].
On this topic, Sussmon et al. already reported that a state
of hypercoagulability may exist in BIH disease [2].
Therefore, this state may also be associated with some
mutations of the genes predisposing to hypercoagulability
such as FV R506Q and FII G20210A and the C677T poly-
morphism in MTHFR gene and cardiovascular genes such
as PAI-1 4G/5G and ACE gene I/D mutation. Moreover,
also an association with antiphospholid antibodies has
been found in our results so acquired thrombophilia
should be considered; antiphospholipid syndrome in fact
may be associated also to several impairments of central
nervous system besides stroke [21].
Our results, throwing light on a compromised haemo-
static balance equilibrium, provide new insights into the
pathogenesis of BIH disease, which may be associated
with high plasma levels in D-Dimer(s), PAI-1, F1+2 and
FPA other than cytologic or chemical abnormalities of
CSF that are able to contribute to the signs and symptoms
of BIH.
The observation of hypercoagulable state and gene poly-
morphisms in a group of patients with BIH disease may
also suggest the hypothesis of an association between
coagulation derangements and venous thrombosis in BIH
pathogenesis.
This hypothesis must be interpreted, however, with cau-
tion, because of the absence of objective instrumental
findings in patients with BIH demonstrating the possibil-
ity that unrecognised non occlusive venous cerebral
thrombus might impede CSF drainage as well as the high
prevalence of gene polymorphisms predisposing to
thrombophilia in the general healthy population. Fur-
thermore, another limitation of our study may be find in
the statistical model because the small number of
enrolled patients compared with an increased of matched
controls but this limit may be due to in part to the severe
criteria that allow BIH diagnosis after a clinical suspect.
In conclusion, according to our findings the association of
hypercoagulability based on biochemical or genetic
Table 3: Mutational state frequence for FV R506Q, PT G20210A, MTHFR C677T, PAI-1 4G/5G, ACE I/D genes in patients and healhty 
subjects (HS).
Gene coagulation mutations Homozygous Wilde-type Heterozygous Homozygous Mutated
Patients (17) HS (51) Patients (17) HS (51) Patients (17) HS (51)
FV R506Q 94% 98% 6% 2% - -
PT G20210A 94% 98% 6% 2% - -
MTHFR C677T 41% 57% 41% 31% 18% 12%
PAI-1 4G/5G 47% 30% 35% 51% 18% 19%
ACE I/D 30% 46% 47% 43% 23% 11%
FV R506Q: factor V Leiden gene polimorphism
PT G20210A: prothrombin G20210A gene polymorphism
MTHFR C677T: Methylenetetrahydrofolate reductase C677T gene polymorphism
PAI-1 4G/5G: plasminogen activator inihibitor 1 4G\5G gene polymorphism
ACE I\D: angiotensin converting enzyme insertion\deletion gene polymorphismPage 5 of 6
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abnormalities and BIH is probably not coincidental, in
particular in subjects with inherited thrombophilia. So,
our data may suggest that some cases of pseudotumor cer-
ebri may recognise a thrombotic pathogenesis; although
based on a small population, our results, in fact, seem to
underline a clear association between hypercoagulable
state, confirmed both with markers of hypercoagulability
(i.e. fibrinopeptide A, prothrombin fragment 1+2 and D-
Dimer) and with tests to look for inherited thrombophilia
(i.e. factor V Leiden, prothrombin A20210G, PAI 4G/5G,
ACE I/D, MTHFR C677T).
However, because based on a small population our data
concerning the involvement of hypercoagulability in the
development of BIH is intriguing and should be con-
firmed on large based randomized clinical trial because
actually we have not chance to screen any type of asymp-
tomatic subject potentially at risk of BIH.
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